- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Oncolys Biopharma Inc (4588)
Oncolys Biopharma Inc stock price live, this page displays TYO 4588 stock exchange data. View the 4588 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Oncolys Biopharma Inc real time stock price chart below.
What Is the Oncolys Biopharma Inc Stock Price Today?
The Oncolys Biopharma Inc stock price today is 602.0.
What Is the Stock Symbol for Oncolys Biopharma Inc?
The stock symbol for Oncolys Biopharma Inc is ""4588.""
What Stock Exchange Does Oncolys Biopharma Inc Trade On?
Oncolys Biopharma Inc is listed and trades on the Tokyo stock exchange.
Is Oncolys Biopharma Inc a Good Stock to Buy?
Determining whether Oncolys Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4588 quote. (ISIN: JP3202170001)
What Is the Oncolys Biopharma Inc Stock Price Today?
The Oncolys Biopharma Inc stock price today is 602.0.
What Is the Stock Symbol for Oncolys Biopharma Inc?
The stock symbol for Oncolys Biopharma Inc is ""4588.""
What Stock Exchange Does Oncolys Biopharma Inc Trade On?
Oncolys Biopharma Inc is listed and trades on the Tokyo stock exchange.
Is Oncolys Biopharma Inc a Good Stock to Buy?
Determining whether Oncolys Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4588 quote. (ISIN: JP3202170001)
Tokyo
Currency in JPY
602.0
+10.0(+1.69%)
Closed·
Fair Value
An estimate of a Oncolys Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
589.0
606.0
52 wk Range
458.0
918.0
4588 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
4588 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Oncolys Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
589.0606.0
52 wk Range
458.0918.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
4588 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Oncolys Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Oncolys Biopharma Inc Company Profile
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company’s product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. Oncolys BioPharma Inc. has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
Compare 4588 to Peers and Sector
Metrics to compare | 4588 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4588PeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.9x | −5.4x | −0.5x | |
PEG Ratio | −0.50 | 0.00 | 0.00 | |
Price/Book | 7.6x | 4.2x | 2.6x | |
Price / LTM Sales | 468.6x | 40.9x | 3.3x | |
Upside (Analyst Target) | - | 75.8% | 42.8% | |
Fair Value Upside | Unlock | 13.9% | 6.5% | Unlock |
Earnings
Latest Release
May 09, 2025
EPS / Forecast
-32.66 / --
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Oncolys Biopharma Trade On?
Oncolys Biopharma is listed and trades on the Tokyo Stock Exchange stock exchange.
What Is the Stock Symbol for Oncolys Biopharma?
The stock symbol for Oncolys Biopharma is "4588."
What Is the Oncolys Biopharma Market Cap?
As of today, Oncolys Biopharma market cap is 14.90B.
What Is Oncolys Biopharma's Earnings Per Share (TTM)?
The Oncolys Biopharma EPS (TTM) is -92.50.
When Is the Next Oncolys Biopharma Earnings Date?
Oncolys Biopharma will release its next earnings report on 07 Aug 2025.
From a Technical Analysis Perspective, Is 4588 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Oncolys Biopharma Stock Split?
Oncolys Biopharma has split 0 times.
How Many Employees Does Oncolys Biopharma Have?
Oncolys Biopharma has 41 employees.
What is the current trading status of Oncolys Biopharma (4588)?
As of 06 Aug 2025, Oncolys Biopharma (4588) is trading at a price of 602.00, with a previous close of 592.00. The stock has fluctuated within a day range of 589.00 to 606.00, while its 52-week range spans from 458.00 to 918.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.